Connect with us

Biotech

Why individualized cancer therapy will revolutionize oncology

BioNTech is a biotechnology company that is working towards revolutionary new cancer treatment methods. The company is headquartered in the upper city of Mainz and has yet to showcase its latest breakthroughs. The company focuses on antibody technology using an individualized approach to improve cancer treatment outcomes.

Published

on

This picture show some bacteria under a microscope.

Founded in 2008, the company focuses on individualized cancer therapies that differ, sometimes considerably, from established treatment methods. Traditional oncology relies on treatment methods such as chemotherapy or radiation therapy, BioNTech pursues an individualized approach for patients with specially developed immune therapies. This allows the immune system to directly target the cancer cells.

Born2Invest is a digital media website covering the biotech industry, among others. Our companion app allows you to get your daily dose of financial news from industries like banking, cannabis, innovation in biotechnology, and many others.

Individualized cancer treatments are the future of oncology

The research program is currently comprised of four classes of active ingredients, with the largest focus placed on so-called “mRNA technology”. This technology uses a substance called messenger RNA (mRNA) to deliver genetic information to cells, which then form proteins to fight cancer cells.

Another area covered is cell therapy, in which the patient’s so-called “T-cells” are modified to target cancer-specific antigens. In addition, BioNTech focuses on antibody technology and the use of so-called “small molecule drugs” that activate the immune system to treat tumors.

Currently, there are over 20 product candidates in the research pipeline against cancer alone. In addition, three others are fighting against other diseases, including influenza. However, there is one speed bump, the active ingredients are currently still in the early stages of clinical testing. Many others are even only in the pre-clinical phase, which means that it will be many years before they can be launched on the market.

BNT122 is currently the most advanced development. The vaccine against metastatic melanoma and other solid tumors is currently in the second phase of clinical trials, with results to date looking very promising. In a recent article, the U.S. magazine Nature quoted a study participant as saying that he had seen the skin cancer cells literally shrink in the weeks following the first injection.

SEE ALSO  How to stay one step ahead of changing customer behaviors

Large pharmaceutical groups such as Sanofi, Pfizer, and Bayer, have already entered into partnerships with the Mainz-based company. Microsoft founder Bill Gates has also attracted attention. The billionaire has invested $56 million (€50 million) in BioNTech through his foundation.

The positive analysts forecasts

Analysts are positive. All the experts covered by Bloomberg rate the share as promising. Bankhaus Berenberg has commented on the third quarter in a study. Naturally, the focus was less on the figures, which are of secondary importance in view of the lack of drugs on the market, instead looking into the research pipeline. According to the analysts, everything is going according to plan. In the case of the product candidate BNT111 for the treatment of advanced melanomas, a rapid transition to a phase 3 study is possible in view of the results obtained so far in the phase 1 study. The experts believe that approval could be granted as early as 2022.

According to Berenberg’s analysts, investors are also still too focused on cancer vaccines and overlook other research approaches. The experts classify BNT321, an antibody for the treatment of pancreatic cancer, and BNT411, a TLR7 agonist against a variety of solid tumors, as “hidden champions”. In preclinical studies, the active substance has achieved better results than other competing immune modulators.

__

(Featured image by Michael Schiffer via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in boerse.de, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Andrew Ross is a features writer whose stories are centered on emerging economies and fast-growing companies. His articles often look at trade policies and practices, geopolitics, mining and commodities, as well as the exciting world of technology. He also covers industries that have piqued the interest of the stock market, such as cryptocurrency and cannabis. He is a certified gadget enthusiast.